Chemiluminescent probes allow for the rapid identification of colibactin-producing bacteria

This study introduces highly sensitive and rapid chemiluminescent probes that selectively target the ClbP enzyme, enabling the direct detection of colibactin-producing *E. coli* in complex stool samples for applications in cancer research and clinical screening.

The Gist

The Big Picture: Finding the "Bad Guys" in Your Gut

Imagine your gut is a bustling city filled with trillions of microscopic residents (bacteria). Most of them are good neighbors, but some are troublemakers. One specific type of troublemaker, a bacteria called E. coli (specifically the "pks+" kind), carries a secret weapon: a toxic chemical called colibactin.

Think of colibactin as a tiny, invisible pair of molecular scissors. When these bacteria release it, the scissors snip and glue together strands of DNA in your cells. Over time, this damage can lead to colorectal cancer.

The problem? These bacteria are sneaky. They don't always show their faces, and the "scissors" (colibactin) are so unstable that they disappear before we can catch them with standard lab tests. Doctors currently have to look for the bacteria's "blueprints" (DNA) to see if they are there, but that doesn't tell us if they are actually using their weapons right now.

The Solution: A "Glow-in-the-Dark" Trap

The scientists in this paper (from Harvard and Tel Aviv University) wanted to build a better trap. Instead of looking for the blueprints, they decided to catch the bacteria in the act of making their weapons.

They created a special chemical probe (let's call it a "Glow-Trap").

1. The Bait: The bacteria have a specific machine inside them called ClbP. This machine is like a factory worker whose only job is to cut open a package to release the toxic colibactin.
2. The Trap: The scientists designed a fake "package" that looks exactly like the real one the ClbP machine likes to cut. However, instead of just a normal package, they hid a glow-in-the-dark firework inside it.
3. The Trigger: When the ClbP machine cuts the fake package, the firework is released. Because it's a special chemical firework (a chemiluminescent probe), it doesn't need a flashlight to glow; it just lights up on its own!

Why This is a Game-Changer

The researchers compared their new "Glow-Traps" to older methods that used regular fluorescent lights (like glow sticks that need to be charged by a UV light first). Here is why the new method is superior:

• Super Brightness (Sensitivity): Imagine trying to hear a whisper in a noisy room. The old method was like trying to hear that whisper while someone else was shouting (background noise). The new method is like having a super-sensitive microphone that picks up the whisper instantly. The new probes are 1,000 times more sensitive than the old ones. They can detect as few as 10,000 to 100,000 bacteria in a drop of liquid.
• Speed: The old method took hours to get a clear signal. The new "Glow-Trap" lights up in under one hour.
• No Background Noise: Regular glow sticks often get confused by the natural glow of other things in the sample (like food particles in poop). The new chemical firework is so bright and specific that it cuts through the noise, making it easy to see the signal even in a messy sample.

The "Poop Test" (Real-World Application)

The ultimate test was to see if this works in real life. The scientists took samples of stool (poop) from mice. Stool is a messy, complex soup of bacteria, food, and mucus.

• They mixed the stool with their new probes.
• If the stool contained the "bad" bacteria with the ClbP machine, the mixture glowed brightly.
• If the stool only had "good" bacteria (or no bacteria), it stayed dark.

They even tested it on stool from mice that had been colonized with a complex mix of human-like gut bacteria. The probe still worked perfectly, lighting up only when the specific "bad" bacteria were present.

Why Should We Care?

This discovery is like upgrading from a magnifying glass to a high-tech metal detector for finding cancer risks.

1. Early Detection: Doctors could potentially use this to screen patients for these dangerous bacteria before cancer develops, allowing for earlier intervention.
2. Drug Testing: If scientists want to find a new drug to stop these bacteria from making their toxic scissors, they can use these probes. If the drug works, the poop sample won't glow. This makes testing new medicines much faster and cheaper.
3. Simplicity: It doesn't require expensive, complex equipment to read the results. If you can see light, you can do the test.

In a Nutshell

The scientists invented a smart, self-lighting chemical tag that only turns on when it meets a specific enzyme found in cancer-linked gut bacteria. It's faster, brighter, and more accurate than anything we had before, offering a promising new tool to spot the early signs of colorectal cancer in the messy reality of the human gut.

Technical Summary

1. Problem Statement

The human gut microbiome contains Enterobacteriaceae (including commensal E. coli) that harbor the pks (or clb) gene cluster. This cluster produces colibactin, a genotoxic natural product that causes DNA interstrand crosslinks and double-strand breaks. Colibactin exposure is strongly linked to colorectal cancer (CRC) development, evidenced by specific mutational signatures (SBS88, ID18) found in CRC tumors.

Despite this link, there is a critical lack of tools to rapidly and accurately detect colibactin-producing bacteria in complex clinical samples (e.g., stool).

• Genetic methods (PCR/LAMP): Require nucleic acid extraction, are time-consuming, and do not confirm if the biosynthetic genes are actually expressed.
• Chemical detection (LC-MS): Colibactin is chemically unstable and difficult to isolate or characterize directly.
• Existing Fluorescent Probes: Previous activity-based probes targeting the biosynthetic enzyme ClbP (a serine peptidase) suffer from high background autofluorescence in biological samples, low sensitivity, and narrow dynamic ranges, making them unsuitable for complex matrices like stool.

2. Methodology

The authors developed a new generation of chemiluminescent activity-based probes designed to detect the enzymatic activity of ClbP.

• Probe Design:

  • The probes mimic the natural substrate of ClbP: an N-acyl-D-asparagine prodrug scaffold.
  • This scaffold is linked to a self-immolative linker and a phenoxy-dioxetane luminophore (a modified Schaap's luminophore).
  • Mechanism: ClbP hydrolyzes the amide bond of the prodrug scaffold. This triggers the self-immolation of the linker, releasing the dioxetane. The dioxetane undergoes chemiexcitation and decays, emitting green photons without the need for external light excitation.
  • Variants: Three probes (2, 3, and 4) were synthesized with different acyl chains (myristoyl vs. 4-phenylbutyryl) and ester modifications (free acid vs. methyl ester) to optimize membrane permeability and signal intensity.

• Experimental Workflow:

  1. In Vitro Characterization: Tested against purified wild-type (WT) ClbP and an inactive mutant (S95A) to confirm specificity.
  2. Bacterial Culture: Tested on E. coli strains expressing the pks cluster (including native strain E. coli Nissle 1917) versus $\Delta$clbP knockouts.
  3. Complex Matrices: Tested in germ-free mouse stool suspensions and stool from mice colonized with Altered Schaedler Flora (ASF) to simulate the human gut microbiome.
  4. Inhibition Studies: Used a known ClbP inhibitor (Compound 13) to verify that the signal reports specific enzymatic activity.

3. Key Contributions

• Development of Chemiluminescent Probes: First application of chemiluminescent activity-based probes specifically for detecting a bacterial enzyme (ClbP) in the context of colibactin production.
• Superior Sensitivity: Demonstrated a >1000-fold increase in sensitivity compared to the best previously reported fluorescent ClbP probes.
• Rapid Detection: Reduced assay time from >2 hours (required for fluorescent probes to overcome background) to <1 hour.
• Direct Stool Detection: Successfully detected pks+ bacteria directly in complex stool suspensions without the need for extensive anaerobic culturing or nucleic acid extraction.

4. Key Results

• Specificity and Signal-to-Noise (S/N):

  • The probes showed high specificity for WT ClbP, with negligible signal from the S95A mutant or blank controls.
  • Probe 4 exhibited a 770-fold higher S/N ratio compared to the fluorescent probe (Probe 1) at equimolar concentrations.
  • The Limit of Detection (LOD) for purified ClbP was 0.17 pM, a 625-fold improvement over fluorescent probes.

• Bacterial Detection Limits:

  • In bacterial cultures, the chemiluminescent probes could detect as few as $1.85 \times 10^4$ to $4.47 \times 10^4$ CFU/mL within 60 minutes.
  • In contrast, the fluorescent probe required an extrapolated LOD of $9.75 \times 10^7$ CFU/mL (a >1000-fold difference in sensitivity).

• Performance in Complex Samples:

  • The probes remained stable in germ-free mouse stool suspensions up to 5 mg/mL.
  • They successfully detected native pks+ E. coli (Nissle 1917, M1/5, ATCC 25922) spiked into germ-free and ASF-colonized stool suspensions within 1 hour.
  • Fluorescent probes failed to produce a detectable signal above background in these same stool samples within the same timeframe.

• Cross-Species Activity:

  • The probes successfully detected ClbP homologs in other colibactin-producing bacteria, including Klebsiella pneumoniae, Erwinia oleae, and Frischella perrara, indicating broad applicability across the Enterobacteriaceae family.

• Inhibition Capability:

  • The probes showed a dose-dependent reduction in luminescence when incubated with ClbP inhibitor 13, confirming their utility for high-throughput screening of inhibitors.

5. Significance

• Clinical Diagnostics: This technology offers a promising path toward a rapid, point-of-care diagnostic for identifying patients at risk for colorectal cancer due to the presence of colibactin-producing bacteria. It overcomes the limitations of genetic testing (which doesn't confirm expression) and chemical detection (which is technically difficult).
• Drug Discovery: The high sensitivity and speed (<1 hour) make these probes ideal for high-throughput screening of libraries to identify new ClbP inhibitors, which could serve as therapeutics to prevent colibactin-induced DNA damage.
• Microbiome Research: The ability to detect specific enzymatic activities in complex microbial communities without culturing provides a powerful tool for studying the functional roles of the gut microbiome in health and disease.
• Future Potential: The authors suggest future optimization could include red-shifted luminophores for in vivo imaging and further miniaturization for clinical deployment.